{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T17:27:56Z","timestamp":1775928476188,"version":"3.50.1"},"reference-count":75,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T00:00:00Z","timestamp":1632355200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010983","name":"Health Research Fund of Central Denmark Region","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010983","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The current treatment for HIV-1 is based on blocking various stages in the viral replication cycle using combination antiretroviral therapy (ART). Even though ART effectively controls the infection, it is not curative, and patients must therefore continue treatment life-long.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>Here we review recent literature investigating the single or combined effect of toll-like receptor (TLR) agonists and broadly neutralizing antibodies (bNAbs) with the objective to evaluate the evidence for this combination as a means towards an HIV-1 cure.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Multiple preclinical studies found significantly enhanced killing of HIV-1 infected cells by TLR agonist-induced innate immune activation or by Fc-mediated effector functions following bNAb administration. However, monotherapy with either agent did not lead to sustained HIV-1 remission in clinical trials among individuals on long-term ART. Notably, findings in non-human primates suggest that a combination of TLR agonists and bNAbs may be able to induce long-term remission after ART cessation and this approach is currently being further investigated in clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Preclinical findings show beneficial effects of either TLR agonist or bNAb administration for enhancing the elimination of HIV-1 infected cells. Further, TLR agonist-mediated stimulation of innate effector functions in combination with bNAbs may enhance antibody-dependent cellular cytotoxicity and non-human primate studies have shown promising results for this combination strategy. Factors such as immune exhaustion, proviral bNAb sensitivity and time of intervention might impact the clinical success.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2021.704617","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T07:12:54Z","timestamp":1632381174000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure"],"prefix":"10.3389","volume":"12","author":[{"given":"Caroline Thue","family":"Hvilsom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole Schmeltz","family":"S\u00f8gaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2021,9,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4108","article-title":"International AIDS Society Global Scientific Strategy: Towards an HIV Cure 2016","volume":"22","author":"Deeks","year":"2016","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.24.13193","article-title":"Presence of an Inducible HIV-1 Latent Reservoir During Highly Active Antiretroviral Therapy","volume":"94","author":"Chun","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1126\/science.278.5341.1295","article-title":"Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy","volume":"278","author":"Finzi","year":"1997","journal-title":"Sci (New York NY)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nm880","article-title":"Long-Term Follow-Up Studies Confirm the Stability of the Latent Reservoir for HIV-1 in Resting CD4+ T Cells","volume":"9","author":"Siliciano","year":"2003","journal-title":"Nat Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv218","article-title":"Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies","volume":"212","author":"Crooks","year":"2015","journal-title":"J Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/44755","article-title":"Re-Emergence of HIV After Stopping Therapy","volume":"401","author":"Chun","year":"1999","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2018.04.030","article-title":"Targeting the Latent Reservoir for HIV-1","volume":"48","author":"Sengupta","year":"2018","journal-title":"Immunity"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070695","article-title":"Differential Natural Killer Cell-Mediated Inhibition of HIV-1 Replication Based on Distinct KIR\/HLA Subtypes","volume":"204","author":"Alter","year":"2007","journal-title":"J Exp Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01112","article-title":"The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies","volume":"11","author":"Martinsen","year":"2020","journal-title":"Front Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1949","article-title":"Neutralizing Antibodies Generated During Natural HIV-1 Infection: Good News for an HIV-1 Vaccine","volume":"15","author":"Stamatatos","year":"2009","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2014.08.007","article-title":"Antibody B Cell Responses in HIV-1 Infection","volume":"35","author":"Mouquet","year":"2014","journal-title":"Trends Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01369-16","article-title":"TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells","volume":"61","author":"Bam","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02166-16","article-title":"Toll-Like Receptor 7 Agonist GS-9620 Induces HIV Expression and HIV-Specific Immunity in Cells From HIV-Infected Individuals on Suppressive Antiretroviral Therapy","volume":"91","author":"Tsai","year":"2017","journal-title":"J Virol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e122673","DOI":"10.1172\/jci.insight.122673","article-title":"Dual TLR2 and TLR7 Agonists as HIV Latency-Reversing Agents","volume":"3","author":"Macedo","year":"2018","journal-title":"JCI Insight"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00222-16","article-title":"A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells","volume":"90","author":"Offersen","year":"2016","journal-title":"J Virol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01163-19","article-title":"PD-1 Blockade and TLR7 Activation Lack Therapeutic Benefit in Chronic Simian Immunodeficiency Virus-Infected Macaques on Antiretroviral Therapy","volume":"63","author":"Bekerman","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B17","doi-asserted-by":"publisher","first-page":"eaao4521","DOI":"10.1126\/scitranslmed.aao4521","article-title":"TLR7 Agonists Induce Transient Viremia and Reduce the Viral Reservoir in SIV-Infected Rhesus Macaques on Antiretroviral Therapy","volume":"10","author":"Lim","year":"2018","journal-title":"Sci Transl Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e127717","DOI":"10.1172\/jci.insight.127717","article-title":"TLR7 Agonist Administration to SIV-Infected Macaques Receiving Early Initiated cART Does Not Induce Plasma Viremia","volume":"4","author":"Del Prete","year":"2019","journal-title":"JCI Insight"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0600-6","article-title":"Antibody and TLR7 Agonist Delay Viral Rebound in SHIV-Infected Monkeys","volume":"563","author":"Borducchi","year":"2018","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"e1009339","DOI":"10.1371\/journal.ppat.1009339","article-title":"TLR7 Agonist, N6-LS and PGT121 Delayed Viral Rebound in SHIV-Infected Macaques After Antiretroviral Therapy Interruption","volume":"17","author":"Hsu","year":"2021","journal-title":"PloS Pathog"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1534","article-title":"Vesatolimod, A Toll-Like Receptor 7 Agonist, Induces Immune Activation in Virally Suppressed Adults With HIV-1","volume":"72","author":"Riddler","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002213","article-title":"Effects of 24-Week Toll-Like Receptor 9 Agonist Treatment in HIV Type 1+ Individuals","volume":"33","author":"Vibholm","year":"2019","journal-title":"Aids"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/emboj\/cdg188","article-title":"HIV Reproducibly Establishes a Latent Infection After Acute Infection of T Cells In Vitro","volume":"22","author":"Jordan","year":"2003","journal-title":"EMBO J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/ar3150","article-title":"Type I IFN and Tnf\u03b1 Cross-Regulation in Immune-Mediated Inflammatory Disease: Basic Concepts and Clinical Relevance","volume":"12","author":"Cantaert","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.9.4531","article-title":"Quantitative Expression of Toll-Like Receptor 1\u201310 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides","volume":"168","author":"Hornung","year":"2002","journal-title":"J Immunol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.99","article-title":"TLR-Mediated Activation of NK Cells and Their Role in Bacterial\/Viral Immune Responses in Mammals","volume":"92","author":"Adib-Conquy","year":"2014","journal-title":"Immunol Cell Biol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.02690-19","article-title":"Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies Against HIV-1-Infected Cells in Plasma From HIV-Infected Subjects","volume":"10","author":"Dupuy","year":"2019","journal-title":"mBio"},{"key":"B28","doi-asserted-by":"publisher","first-page":"10844","DOI":"10.1038\/ncomms10844","article-title":"Elimination of HIV-1-Infected Cells by Broadly Neutralizing Antibodies","volume":"7","author":"Bruel","year":"2016","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00347-16","article-title":"Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies","volume":"90","author":"von Bredow","year":"2016","journal-title":"J Virol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00634-17","article-title":"Comprehensive Cross-Clade Characterization of Antibody-Mediated Recognition, Complement-Mediated Lysis, and Cell-Mediated Cytotoxicity of HIV-1 Envelope-Specific Antibodies Toward Eradication of the HIV-1 Reservoir","volume":"91","author":"Mujib","year":"2017","journal-title":"J Virol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00895-18","article-title":"Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates With Infected Cell Binding for a Panel of Clade B HIV Reactivated From Latent Reservoirs","volume":"92","author":"Ren","year":"2018","journal-title":"J Virol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02051-18","article-title":"Establishment of a Novel Humanized Mouse Model To Investigate In Vivo Activation and Depletion of Patient-Derived HIV Latent Reservoirs","volume":"93","author":"Flerin","year":"2019","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1279","article-title":"Enhanced Clearance of HIV-1-Infected Cells by Broadly Neutralizing Antibodies Against HIV-1 In Vivo","volume":"352","author":"Lu","year":"2016","journal-title":"Science (New York NY)"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30053-0","article-title":"Safety and Efficacy of VRC01 Broadly Neutralising Antibodies in Adults With Acutely Treated HIV (RV397): A Phase 2, Randomised, Double-Blind, Placebo-Controlled Trial","volume":"6","author":"Crowell","year":"2019","journal-title":"Lancet HIV"},{"key":"B35","doi-asserted-by":"publisher","first-page":"ofy242","DOI":"10.1093\/ofid\/ofy242","article-title":"Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 on HIV-1 Persistence in Individuals on Effective ART","volume":"5","author":"Riddler","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"B36","doi-asserted-by":"publisher","first-page":"e1006987","DOI":"10.1371\/journal.ppat.1006987","article-title":"HIV-Specific Fc Effector Function Early in Infection Predicts the Development of Broadly Neutralizing Antibodies","volume":"14","author":"Richardson","year":"2018","journal-title":"PloS Pathog"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.21084","article-title":"High-Throughput Quantitative Analysis of HIV-1 and SIV-Specific ADCC-Mediating Antibody Responses","author":"Pollara","year":"2011","journal-title":"Cytometry A"},{"key":"B38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.jim.2005.09.018","article-title":"A Simplified Method for the Rapid Fluorometric Assessment of Antibody-Dependent Cell-Mediated Cytotoxicity","volume":"308","author":"G\u00f3mez-Rom\u00e1n","year":"2006","journal-title":"J Immunol Methods"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jim.2012.07.006","article-title":"Role of Monocytes in Mediating HIV-Specific Antibody-Dependent Cellular Cytotoxicity","volume":"384","author":"Kramski","year":"2012","journal-title":"J Immunol Methods"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00358-18","article-title":"Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses","volume":"9","author":"Richard","year":"2018","journal-title":"mBio"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1083182","article-title":"Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition","volume":"300","author":"Calarese","year":"2003","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1128\/JVI.01564-08","article-title":"Design and Expression of a Dimeric Form of Human Immunodeficiency Virus Type 1 Antibody 2G12 With Increased Neutralization Potency","volume":"83","author":"West","year":"2009","journal-title":"J Virol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-017-3992-9","article-title":"In Vitro Inhibition of HIV-1 Replication in Autologous CD4(+) T Cells Indicates Viral Containment by Multifactorial Mechanisms","volume":"32","author":"Tu","year":"2017","journal-title":"Virol Sin"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02108-09","article-title":"Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies","volume":"84","author":"Seaman","year":"2010","journal-title":"J Virol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090378","article-title":"Genetic Identity, Biological Phenotype, and Evolutionary Pathways of Transmitted\/Founder Viruses in Acute and Early HIV-1 Infection","volume":"206","author":"Salazar-Gonzalez","year":"2009","journal-title":"J Exp Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3158","article-title":"Antibody Responses to Envelope Glycoproteins in HIV-1 Infection","volume":"16","author":"Burton","year":"2015","journal-title":"Nat Immunol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nri.2017.106","article-title":"Beyond Binding: Antibody Effector Functions in Infectious Diseases","volume":"18","author":"Lu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.663919","article-title":"Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir","volume":"12","author":"Suryawanshi","year":"2021","journal-title":"Front Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"e74858","DOI":"10.1371\/journal.pone.0074858","article-title":"Comparative Efficiency of HIV-1-Infected T Cell Killing by NK Cells, Monocytes and Neutrophils","volume":"8","author":"Smalls-Mantey","year":"2013","journal-title":"PloS One"},{"key":"B50","doi-asserted-by":"publisher","first-page":"100254","DOI":"10.1016\/j.xcrm.2021.100254","article-title":"Improved HIV-Positive Infant Survival Is Correlated With High Levels of HIV-Specific ADCC Activity in Multiple Cohorts","volume":"2","author":"Yaffe","year":"2021","journal-title":"Cell Rep Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00244","article-title":"IgA Targeting Human Immunodeficiency Virus-1 Envelope Gp41 Triggers Antibody-Dependent Cellular Cytotoxicity Cross-Clade and Cooperates With Gp41-Specific IgG to Increase Cell Lysis","volume":"9","author":"Duchemin","year":"2018","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1301456110","article-title":"Vaccine-Induced Plasma IgA Specific for the C1 Region of the HIV-1 Envelope Blocks Binding and Effector Function of IgG","volume":"110","author":"Tomaras","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02363-15","article-title":"Env-Specific IgA From Viremic HIV-Infected Subjects Compromises Antibody-Dependent Cellular Cytotoxicity","volume":"90","author":"Ruiz","year":"2016","journal-title":"J Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1172\/JCI122466","article-title":"Fc-Dependent Functions Are Redundant to Efficacy of Anti-HIV Antibody PGT121 in Macaques","volume":"129","author":"Parsons","year":"2019","journal-title":"J Clin Invest"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e0219142","DOI":"10.1371\/journal.pone.0219142","article-title":"Safety, Pharmacokinetics, and Immunogenicity of the Combination of the Broadly Neutralizing Anti-HIV-1 Antibodies 3BNC117 and 10-1074 in Healthy Adults: A Randomized, Phase 1 Study","volume":"14","author":"Cohen","year":"2019","journal-title":"PloS One"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411","article-title":"Viraemia Suppressed in HIV-1-Infected Humans by Broadly Neutralizing Antibody 3BNC117","volume":"522","author":"Caskey","year":"2015","journal-title":"Nature"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268","article-title":"Antibody 10-1074 Suppresses Viremia in HIV-1-Infected Individuals","volume":"23","author":"Caskey","year":"2017","journal-title":"Nat Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination Therapy With Anti-HIV-1 Antibodies Maintains Viral Suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/nature18929","article-title":"HIV-1 Antibody 3BNC117 Suppresses Viral Rebound in Humans During Treatment Interruption","volume":"535","author":"Scheid","year":"2016","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI135557","article-title":"Improved Killing of HIV-Infected Cells Using Three Neutralizing and Non-Neutralizing Antibodies","volume":"130","author":"Tuyishime","year":"2020","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and Pharmacokinetics of the Fc-Modified HIV-1 Human Monoclonal Antibody VRC01LS: A Phase 1 Open-Label Clinical Trial in Healthy Adults","volume":"15","author":"Gaudinski","year":"2018","journal-title":"PloS Med"},{"key":"B63","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/cei.12692","article-title":"Safety, Pharmacokinetics and Neutralization of the Broadly Neutralizing HIV-1 Human Monoclonal Antibody VRC01 in Healthy Adults","volume":"182","author":"Ledgerwood","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/nature13612","article-title":"Enhanced Neonatal Fc Receptor Function Improves Protection Against Primate SHIV Infection","volume":"514","author":"Ko","year":"2014","journal-title":"Nature"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008236117","article-title":"Fc-Mediated Effector Function Contributes to the In Vivo Antiviral Effect of an HIV Neutralizing Antibody","volume":"117","author":"Asokan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nature17677","article-title":"A Single Injection of Anti-HIV-1 Antibodies Protects Against Repeated SHIV Challenges","volume":"533","author":"Gautam","year":"2016","journal-title":"Nature"},{"key":"B67","article-title":"Foster City, CA, USA. GS-9722: First-In-Class Effector-Enhanced Broadly Neutralizing Antibody for HIV Cure","author":"Thomsen ND","year":"2019"},{"key":"B68","doi-asserted-by":"publisher","first-page":"108502","DOI":"10.1016\/j.celrep.2020.108502","article-title":"HIV Antibody Fc N-Linked Glycosylation Is Associated With Viral Rebound","volume":"33","author":"Offersen","year":"2020","journal-title":"Cell Rep"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3HI1217-500R","article-title":"Frontline Science: Plasma and Immunoglobulin G Galactosylation Associate With HIV Persistence During Antiretroviral Therapy","volume":"104","author":"Vadrevu","year":"2018","journal-title":"J Leukoc Biol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/nature12744","article-title":"Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys","volume":"503","author":"Barouch","year":"2013","journal-title":"Nature"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.7326\/M14-1027","article-title":"Antiretroviral-Free HIV-1 Remission and Viral Rebound After Allogeneic Stem Cell Transplantation: Report of 2 Cases","volume":"161","author":"Henrich","year":"2014","journal-title":"Ann Intern Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1120248109","article-title":"Immediate Antiviral Therapy Appears to Restrict Resting CD4+ Cell HIV-1 Infection Without Accelerating the Decay of Latent Infection","volume":"109","author":"Archin","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01046-14","article-title":"Long-Term Antiretroviral Treatment Initiated at Primary HIV-1 Infection Affects the Size, Composition, and Decay Kinetics of the Reservoir of HIV-1-Infected CD4 T Cells","volume":"88","author":"Buzon","year":"2014","journal-title":"J Virol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/COH.0000000000000122","article-title":"How Does the Timing of Antiretroviral Therapy Initiation in Acute Infection Affect HIV Reservoirs","volume":"10","author":"Ananworanich","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001148","article-title":"Virologic Failure Is Uncommon After Treatment Initiation During Acute HIV Infection","volume":"30","author":"Crowell","year":"2016","journal-title":"AIDS"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.704617\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T07:12:58Z","timestamp":1632381178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.704617\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,23]]},"references-count":75,"alternative-id":["10.3389\/fimmu.2021.704617"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.704617","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,23]]},"article-number":"704617"}}